Briefing
Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study.
The methylation-based tissue-free Latitude assay was tested on 1,230 time points from 195 people in GALAXY, and ctDNA positivity was associated with worse disease-free survival in both the residual-disease and surveillance windows.
- Design: Evidence level 2
- Assay: Latitude
NPJ Precision OncologyPubMed 41555007DOI 10.1038/s41698-026-01277-5